NLRP3 and acute myeloid leukemia: Furthermore, AML patients with low expression of TXNIP, NLRP3 and IL1B had a longer survival time compared to those with high expression of either gene or all three genes (1-year OS: TXNIPlowNLRP3lowIL1Blow vs. TXNIPhighNLRP3highIL1Bhigh vs. TXNIPhigh or NLRP3high or IL1Bhigh, 100% vs 33% vs 57%, P = 0.026, Figure 4D and 4E).